Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - cyclophosphamidum inn - tafla - 50 mg

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - cyclophosphamidum inn - stungulyfsstofn, lausn - 1 g

Island - islandsk - LYFJASTOFNUN (Icelandic Medicines Agency)

baxter medical ab* - cyclophosphamidum inn - stungulyfsstofn, lausn - 500 mg

Den Europæiske Union - islandsk - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - mergæxli - Æxlishemjandi lyf - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.